News about Clinical Trials

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Clinical Trials | 01/10/2026 | By News Bureau

Acurx Enrolls First Patient in PATHFINDER C. difficile Trial

Acurx Pharmaceuticals has announced the first patient enrolled in PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.

Clinical Trials | 01/10/2026 | By News Bureau

Lilly's Zepbound Shows More Weight Loss Than Wegovy HD in Analysis

Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with greater weight loss than Wegovy HD (semaglutide 7.2 mg) in an indirect comparison.

Clinical Trials | 01/10/2026 | By News Bureau

Silexion Reports Positive Findings for RNAi Candidate SIL204

Silexion Therapeutics reports new findings supporting the cellular uptake and gene-silencing mechanism of its investigational RNAi candidate SIL204.

Clinical Trials | 30/09/2026 | By News Bureau

Mirum's Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta

Mirum Pharmaceuticals reports positive Phase 3 AZURE-1 results for brelovitug, with the investigational antibody meeting its primary endpoint in chronic HDV.

Clinical Trials | 29/09/2026 | By News Bureau

Innovent Expands Phase 3 MarsLight-11 NSCLC Study

Innovent expands the global phase 3 MarsLight-11 study of IBI363/TAK-928 in immunotherapy-resistant NSCLC to include non-squamous NSCLC patients.

Clinical Trials | 29/09/2026 | By News Bureau

BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma

Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.

Clinical Trials | 28/09/2026 | By News Bureau

Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study

Newron’s ENIGMA-TRS 2 study continues outside the US, with expanded sites and enrollment in Europe, Asia and Latin America; topline data expected in Q1 2027.

Clinical Trials | 28/09/2026 | By News Bureau

Astellas Advances Setidegrasib Into Phase 3 Trial for NSCLC

Astellas has dosed the first patient in a Phase 3 study evaluating setidegrasib against docetaxel in patients with KRAS G12D-mutated NSCLC.

Clinical Trials | 25/09/2026 | By News Bureau |  106

Roche's Sefaxersen Cuts Proteinuria in IgA Nephropathy

Roche’s sefaxersen significantly reduces proteinuria in IgA nephropathy, with Phase III IMAgINATION data showing meaningful results versus placebo.

Clinical Trials | 24/09/2026 | By News Bureau